Researchers at U of T Engineering have developed a new way of growing realistic human tissues outside the body. Their “person-on-a-chip” technology, called AngioChip, is a powerful platform for discovering and testing new drugs, and could eventually be used to repair or replace damaged organs.
Professor Milica Radisic (IBBME, ChemE), graduate student Boyang Zhang and their collaborators are among those research groups around the world racing to find ways to grow human tissues in the lab, under conditions that mimic a real person’s body. They have developed unique methods for manufacturing small, intricate scaffolds for individual cells to grow on. These artificial environments produce cells and tissues that resemble the real thing more closely than those grown lying flat in a petri dish.
he team’s recent creations have included BiowireTM — an innovative method of growing heart cells around a silk suture — as well as a scaffold for heart cells that snaps together like sheets of Velcro™. But AngioChip takes tissue engineering to a whole new level. “It’s a fully three-dimensional structure complete with internal blood vessels,” says Radisic. “It behaves just like vasculature, and around it there is a lattice for other cells to attach and grow.” The work — which is published todayin the journal Nature Materials — was produced collaboratively with researchers from across U of T, including Professor Michael Sefton (ChemE, IBBME), Professor Aaron Wheeler (Chemistry, IBBME) and their research teams, as well as researchers from Toronto General Hospital and University Health Network.
Zhang built the scaffold out of POMaC, a polymer that is both biodegradable and biocompatible. The scaffold is built out of a series of thin layers, stamped with a pattern of channels that are each about 50 to 100 micrometres wide. The layers, which resemble the computer microchips, are then stacked into a 3D structure of synthetic blood vessels. As each layer is added, UV light is used to cross-link the polymer and bond it to the layer below.
When the structure is finished, it is bathed in a liquid containing living cells. The cells quickly attach to the inside and outside of the channels and begin growing just as they would in the human body.
“Previously, people could only do this using devices that squish the cells between sheets of silicone and glass,” says Radisic. “You needed several pumps and vacuum lines to run just one chip. Our system runs in a normal cell culture dish, and there are no pumps; we use pressure heads to perfuse media through the vasculature. The wells are open, so you can easily access the tissue.”
Using the platform, the team has built model versions of both heart and liver tissues that function like the real thing. “Our liver actually produced urea and metabolized drugs,” says Radisic. They can connect the blood vessels of the two artificial organs, thereby modelling not just the organs themselves, but the interactions between them. They’ve even injected white blood cells into the vessels and watched as they squeezed through gaps in the vessel wall to reach the tissue on the other side, just as they do in the human body.
AngioChip has great potential in the field of pharmaceutical testing. Current drug-testing methods, such as animal testing and controlled clinical trials, are costly and fraught with ethical concerns. Testing on lab-grown human tissues would provide a realistic model at a fraction of the cost, but this area of research is still in its infancy. “In the last few years, it has become possible to order cultures of human cells for testing, but they’re grown on a plate, a two-dimensional environment,” says Radisic. “They don’t capture all the functional hallmarks of a real heart muscle, for example.”
A more realistic platform like AngioChip could enable drug companies to detect dangerous side effects and interactions between organ compartments long before their products reach the market, saving countless lives. It could also be used to understand and validate the effectiveness of current drugs and even to screen libraries of chemical compounds to discover new drugs. Through TARA Biosystems Inc., a spin-off company co-founded by Radisic, the team is already working on commercializing the technology.
In future, Radisic envisions her lab-grown tissues being implanted into the body to repair organs damaged by disease. Because the cells used to seed the platform can come from anyone, the new tissues could be genetically identical to the intended host, reducing the risk of organ rejection. Even in its current form, the team has shown that the AngioChip can be implanted into a living animal, its artificial blood vessels connected to a real circulatory system. The polymer scaffolding itself simply biodegrades after several months.
The Latest on: Tissue engineering
via Google News
The Latest on: Tissue engineering
- New Paper Defines Breakthroughs in Vascular Tissue Engineeringon October 9, 2020 at 5:41 am
A new manuscript published in the highly cited scientific journal Science (also known as Science Magazine) reveals great strides in the field of regenerative medicine and vascular tissue engineering.
- Researchers provide unique experiment for creating artificial tissue-engineered vascular grafton October 8, 2020 at 7:25 pm
Researchers from St. Petersburg provided a unique experiment. They implanted a polymer scaffold as a vascular prosthesis into the rat abdominal aorta and monitored the process of its bioresobtion for ...
- Harvard Researchers Discover New Genetic Source of Tissue Formationon October 7, 2020 at 8:45 pm
The finding could have momentous implications for developing disease treatments, according to experts, allowing for a better understanding of how cells divide and form larger tissues.
- Tissue Regenix Group (LON:TRX) Share Price Crosses Below 200 Day Moving Average of $0.48on October 7, 2020 at 1:32 am
Tissue Regenix Group PLC (LON:TRX)’s stock price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.48 and traded as low as $0.35. Tissue ...
- Experts to Study Human Tissue Models’ Responses to Space Radiation, and Develop Countermeasureson October 2, 2020 at 7:47 am
With an award from the Translational Research Institute for Space Health (TRISH) at Baylor College of Medicine, a partner to the NASA Human Research Program, Sharon Gerecht will lead a team that will ...
- Asia Pacific Tissue Engineering Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Material Type, Applications, and Countryon October 1, 2020 at 2:56 pm
Reportlinker.com announces the release of the report "Asia Pacific Tissue Engineering Market Forecast to 2027 - COVID-19 ...
- Europe Tissue Engineering Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Material Type, Applications, and Countryon October 1, 2020 at 5:47 am
The market growth is primarily attributed to the increasing incidences of chronic diseases, road accidents, and trauma injuries, and technological advancements in 3D tissue engineering techniques.High ...
- North America Tissue Engineering Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Material Type, Applications, and Countryon September 26, 2020 at 3:40 am
26, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "North America Tissue Engineering Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Material Type ...
- Tissue Engineering and COVID-19 Impact Analysis, Market Size, Growth, Competitive Strategies, and Worldwide Demand During 2020-2027on September 25, 2020 at 8:18 am
A report by The Insight Partner's on the Tissue Engineering market discusses the growth of the market in great detail. It discusses thoroughly all factors promoting and deterring the market.
- Tissue Engineering Market Overall Study Report with Top Key Playerson September 20, 2020 at 7:39 pm
Sep 21, 2020 (AmericaNewsHour) -- Global Tissue Engineering Market valued approximately USD 5.1 million in 2016 is anticipated to grow with a healthy growth rate of more than 20.4% over the ...
via Bing News